Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance

Ticker(s): IOVA

Who's the expert?

Name: Dr Tobias Schatton - PHD

Institution: Harvard

  • Assistant Professor of Dermatology at Harvard Medical School, a Research Associate at the Department of Dermatology at Brigham and Women’s Hospital and the Department of Medicine at Boston Children’s Hospital, and Affiliated Faculty Faculty Member of the Harvard Stem Cell Institute.
  • Laboratory research centers on immune checkpoint pathways in melanoma and other skin cancers.
  • Study focuses on previously unrecognized skin- and cancer cell-intrinsic vs. tumor-infiltrating lymphocyte (TIL)-specific roles of the PD-1:PD-1 ligand and Tim-3:Gal-9 axes in tumor immune evasion and cancer progression.

Interview Questions

Please describe your clinical practice as it relates to cancer immunotherapies.

Added By: c_admin

Can you briefly explain TIL as a mechanism of action?

Added By: c_admin

What are your thoughts on Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.